Lung cancer radiotherapy might improve immune checkpoint blockade-associated survival

Prior radiotherapy is associated with longer survival times among patients administered pembrolizumab immunotherapy for non–small cell lung cancer, according to an analysis of data from the phase 1 KEYNOTE-001 trial. The findings appear to bolster preclinical research linking radiotherapy to enhanced anti-tumour immune activity.
Cancer Therapy Advisor